Non-small cell lung cancer · line 1 · Pembrolizumab + carboplatin + pemetrexed (NSCLC non-squamous, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-PEMBRO-CHEMO-NSCLC-NONSQ`

ID	`IND-NSCLC-PDL1-LOW-NONSQ-MET-1L`
Type	Indication
Status	status not declared
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-KEYNOTE-189-GANDHI-2018` `SRC-NCCN-NSCLC-2025`

Notes

KEYNOTE-189: pembro + carbo + pemetrexed superior to chemo alone in non-squamous PD-L1<50% driver-negative metastatic. KEYNOTE-407 parallel for squamous (with paclitaxel instead of pemetrexed).

Used By

Algorithms

ALGO-NSCLC-METASTATIC-1L - ALGO-NSCLC-METASTATIC-1L

Handbook Chapters

HB-NSCLC-METASTATIC-1L - Metastatic NSCLC: driver-first treatment reasoning